E-theraputics and Novo Nordisk extend research collaboration on type II diabetes trial

E-theraputics and Novo Nordisk have extended their collaboration in the type II diabetes space to discover biological mechanisms and therapeutic approaches for the condition using E-theraputics Network Driven Drug Discover (NDD).

The amendment extends the original contract by six months (to June 2020), and allows further work to be performed on the NDD technology, as well as allow E-theraputics to use its new Genome Associated Interaction Networks (GAIN) to analyse data from patients.
“We’re really pleased to extend our original agreement with Novo Nordisk.” Said Dr Ray Barlow, CEO at E-theraputics. “We’re really excited by the potential of GAINS and its potential to improve our understanding of complex diseases, and the pathways and processes that come with into discovering new drugs for treatments.”